Perkinelmer Inc PKI
We take great care to ensure that the data presented and summarized in this overview for PERKINELMER INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PKI
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD17MShares$2.06 Billion1.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$1.71 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY8.71MShares$1.05 Billion0.02% of portfolio
-
Select Equity Group, L.P. New York, NY8.08MShares$977 Million3.63% of portfolio
-
Janus Henderson Group PLC London, X05.66MShares$685 Million0.38% of portfolio
-
State Street Corp Boston, MA5.2MShares$629 Million0.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA3.71MShares$449 Million0.1% of portfolio
-
Morgan Stanley New York, NY2.82MShares$341 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.79MShares$337 Million0.03% of portfolio
-
Pictet Asset Management Sa Geneva 73, V82.13MShares$258 Million0.0% of portfolio
Latest Institutional Activity in PKI
Top Purchases
Top Sells
About PKI
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Insider Transactions at PKI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 01
2024
|
Alexis P Michas |
BUY
Grant, award, or other acquisition
|
Direct |
2,586
+2.2%
|
-
|
May 01
2024
|
Michael A Klobuchar |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+35.7%
|
-
|
May 01
2024
|
Michelle Mc Murry Heath |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+20.09%
|
-
|
May 01
2024
|
Michel Vounatsos |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+11.2%
|
-
|
May 01
2024
|
Frank Witney |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+5.72%
|
-
|
May 01
2024
|
Samuel R. Chapin |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+5.92%
|
-
|
May 01
2024
|
Pascale Witz |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+9.29%
|
-
|
May 01
2024
|
Peter Barrett |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+4.54%
|
-
|
May 01
2024
|
Sophie V. Vandebroek |
BUY
Grant, award, or other acquisition
|
Direct |
2,195
+35.7%
|
-
|
Apr 15
2024
|
Anita Gonzales |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-2.51%
|
$11,124
$103.49 P/Share
|
Mar 26
2024
|
Prahlad R. Singh |
BUY
Bona fide gift
|
Indirect |
12,075
+24.52%
|
-
|
Mar 26
2024
|
Prahlad R. Singh |
SELL
Bona fide gift
|
Direct |
12,075
-11.81%
|
-
|
Mar 01
2024
|
Anita Gonzales |
BUY
Grant, award, or other acquisition
|
Direct |
715
+14.24%
|
-
|
Feb 29
2024
|
Alexis P Michas |
SELL
Open market or private sale
|
Direct |
5,000
-8.25%
|
$545,000
$109.98 P/Share
|
Feb 27
2024
|
Tajinder S Vohra |
SELL
Open market or private sale
|
Direct |
7,918
-12.29%
|
$831,390
$105.25 P/Share
|
Feb 27
2024
|
Tajinder S Vohra |
BUY
Exercise of conversion of derivative security
|
Direct |
7,918
+18.88%
|
$427,572
$54.56 P/Share
|
Feb 23
2024
|
Prahlad R. Singh |
SELL
Open market or private sale
|
Direct |
1,144
-1.11%
|
$120,120
$105.13 P/Share
|
Feb 23
2024
|
Joel S Goldberg |
SELL
Open market or private sale
|
Direct |
835
-2.0%
|
$87,675
$105.13 P/Share
|
Feb 15
2024
|
Anita Gonzales |
SELL
Payment of exercise price or tax liability
|
Direct |
119
-1.62%
|
$12,257
$103.56 P/Share
|
Feb 15
2024
|
Maxwell Krakowiak |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-0.59%
|
$8,755
$103.56 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 22.4K shares |
---|---|
Exercise of conversion of derivative security | 103K shares |
Bona fide gift | 12.1K shares |
Payment of exercise price or tax liability | 21.9K shares |
---|---|
Bona fide gift | 12.6K shares |
Open market or private sale | 51.6K shares |